Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 202 clinical trials
Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction (IDA53)

-stage clinical trials found daratumumab to be safe and to display encouraging clinical activity as a single agent in relapsed/refractory multiple myeloma (MM) patients (Lockhorst et al 2016, Lonial et

  • 2 views
  • 06 Feb, 2022
  • 4 locations
HB10101 Multiple Myeloma

It is a phase one study with dose escalation and safety CART in BCMA- Expressing Multiple Myeloma Patients

  • 0 views
  • 03 Feb, 2021
  • 1 location
First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma

2 dose regimen (RP2DR) of REGN5458 as monotherapy in patients with relapsed or refractory multiple myeloma (MM). In the phase 2 portion of the study: To assess the anti-tumor activity of

lenalidomide
immunomodulatory imide drug
immunotherapeutic agent
refractory multiple myeloma
proteasome inhibitor
  • 24 views
  • 08 Apr, 2022
  • 20 locations
A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma

This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX120 in subjects with relapsed or refractory multiple myeloma.

refractory multiple myeloma
  • 37 views
  • 25 Feb, 2022
  • 10 locations
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma (DREAMM 8)

and dexamethasone (Arm B) in participants with relapsed/refractory multiple myeloma (RRMM).

dexamethasone
lenalidomide
cancer
bortezomib
measurable disease
  • 19 views
  • 24 May, 2022
  • 116 locations
A Study of Teclistamab, in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-1)

The purpose of this study is evaluate the efficacy of teclistamab at the recommended Phase 2 dose (RP2D).

measurable disease
multiple myeloma
  • 0 views
  • 09 Jun, 2022
  • 9 locations
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the efficacy of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).

measurable disease
multiple myeloma
  • 0 views
  • 29 Jun, 2022
  • 61 locations
Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to characterize the safety of Talquetamab and to determine the recommended Phase 2 dose(s) (RP2Ds) and dosing schedule assessed to be safe for Talquetamab (Part 1 [Dose Escalation]) and to further characterize the safety of Talquetamab at the recommended Phase 2 dose(s) (RP2Ds) (Part …

measurable disease
human chorionic gonadotropin
multiple myeloma
  • 65 views
  • 30 Jun, 2022
  • 12 locations
Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

This is a phase I, multicenter, open-label, dose-escalation study of cevostamab administered as a single agent by IV infusion to participants with relapsed or refractory multiple myeloma (R/R MM

measurable disease
cancer
refractory multiple myeloma
  • 257 views
  • 03 Jul, 2022
  • 17 locations
A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

part to gather further safety data for AMG 701 monotherapy at the RP2D in adult subjects with relapsed/refractory multiple myeloma (RRMM). In addition, this study will include a sequential dose

  • 252 views
  • 17 Jun, 2022
  • 29 locations